Page 1 | Search Results | Blood Neoplasia | American Society of Hematology

1-20 of 127

Sort by

Sort Order Select

Journal Articles

Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis

Aaron S. Rosenberg, Emanual Maverakis, Caitlin Costello, Elizabeth A. Brem, Matthew Joseph Wieduwilt, Guillaume Luxardi, Paul Kaesberg, Keon Abedi, Samantha Herbert, Joseph Tuscano

Blood Neoplasia (2025) 2 (3): 100067.

https://doi.org/10.1016/j.bneo.2025.100067

Published: 2025

Includes: Supplemental data

Journal Articles

TYK2 is essential for the therapeutic effect of IFN-α in Jak2 V617F-induced murine myeloproliferative neoplasms

Blood Neoplasia (2025) 2 (3): 100087.

https://doi.org/10.1016/j.bneo.2025.100087

Published: 2025

Includes: Supplemental data

Journal Articles

Tumor-associated myeloid cells support murine T-ALL in the central nervous system via integrin signaling

Ryan S. Humphrey, Seohee Nam, Dennis C. Wylie, Lauren I. R. Ehrlich

Blood Neoplasia (2025) 2 (3): 100095.

https://doi.org/10.1016/j.bneo.2025.100095

Published: 2025

Includes: Supplemental data

Journal Articles

Risk factors and clinical impact of cytomegalovirus DNAemia in patients with multiple myeloma treated with teclistamab

Charles Pei, Zeinab El Boghdadly, Lisa Blackburn, Nidhi Sharma, Naresh Bumma, Abdullah M. Khan, Srinivas Devarakonda, Elvira Umyarova, Don Benson, Ashley Rosko, Francesca Cottini

Blood Neoplasia (2025) 2 (3): 100097.

https://doi.org/10.1016/j.bneo.2025.100097

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm

Suravi Raychaudhuri, Ted A. Gooley, Allegra Rasmussen, Kim Quach, Eva Gill, Anna B. Halpern, Jacob S. Appelbaum, Cristina M. Ghiuzeli, Paul C. Hendrie, Ryan D. Cassaday, Roland B. Walter, Mary-Elizabeth M. Percival

Blood Neoplasia (2025) 2 (3): 100085.

https://doi.org/10.1016/j.bneo.2025.100085

Published: 2025

Includes: Supplemental data

Journal Articles

A Phase 1 Study of IO-202, an Anti-LILRB4 Antibody, in Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia

Blood Neoplasia 100126.

https://doi.org/10.1016/j.bneo.2025.100126

Published: 2025

Includes: Supplemental data

Journal Articles

Correlates of Organ Damage in Advanced Systemic Mastocytosis Patients Enrolled in Clinical Trials of Avapritinib

Emily C. Liang, Cecelia Perkins, Rong Lu, Hongliang Shi, Saša Dimitrijević, Justin Abuel, Cheryl Langford, Parveen Abidi, Lenn Fechter, William Shomali, Jason Gotlib

Blood Neoplasia 100127.

https://doi.org/10.1016/j.bneo.2025.100127

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: A Danish population-based study

Trine Trab, Iman Chanchiri, Ahmed Ludvigsen Al-Mashhadi, Emma Berggreen Dall, Stine Rasch, Mette Johansen, Simon Husby, Mikkel Runason Simonsen, Michael Roost Clausen, Thomas Stauffer Larsen, Jacob Haaber Christensen, Robert Schou Pedersen, Mikael Frederiksen, Mats Jerkeman, Christian Bjørn Poulsen, Laura Mors Haunstrup, Peter Brown, Tarec Christoffer El-Galaly, Kirsten Grønbæk

Blood Neoplasia 100128.

https://doi.org/10.1016/j.bneo.2025.100128

Published: 2025

Includes: Supplemental data

Journal Articles

Targeting scavenger receptor class B type 1 with a bioinspired ligand induces apoptosis or ferroptosis in AML

Adam Y. Lin, Jonathan S. Rink, Eva Yang, Sara Small, Jessica J. Gerber, Taylor J Zak, Jessica Altman, Yasmin Abaza, Leonidas C. Platanias, Leo I Gordon, C. Shad Thaxton

Blood Neoplasia 100122.

https://doi.org/10.1016/j.bneo.2025.100122

Published: 2025

Includes: Supplemental data

Journal Articles

V-FAST: A phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML

Vinod A. Pullarkat, Mark Levis, James McCloskey, Gabriel N. Mannis, Stephen A. Strickland, Amir T. Fathi, Tara L. Lin, Vijaya R. Bhatt, Thuva Vanniyasingam, Divya Chakravarthy, Yana Lutska, Stefan Faderl, Ronald S. Cheung, Harry P. Erba

Blood Neoplasia 100123.

https://doi.org/10.1016/j.bneo.2025.100123

Published: 2025

Includes: Supplemental data

Journal Articles

Beat AML genetic risk stratification model in an older VEN/HMA-treated AML patient cohort

Fieke W. Hoff, Ashley O. Yocum, Uma M. Borate, Alice S. Mims, John C. Byrd, Yazan F. Madanat

Blood Neoplasia 100125.

https://doi.org/10.1016/j.bneo.2025.100125

Published: 2025

Includes: Supplemental data

Journal Articles

Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma.

Tadeusz Kubicki, Benjamin A Derman, Jennifer H Cooperrider, Anna Puła, David Barnidge, Dominik Dytfeld, Ken Jiang, Andrzej J Jakubowiak

Blood Neoplasia 100124.

https://doi.org/10.1016/j.bneo.2025.100124

Published: 2025

Includes: Supplemental data

Journal Articles

Moura PL, Nannya Y, Aliouat A, et al. Competition of dual SF3B1 mt clones in MDS-RS is associated with distinct RNA mis-splicing in hematopoietic stem cells. Blood Neoplasia. 2024;1(2):100011.

Blood Neoplasia (2025) 2 (2): 100088.

https://doi.org/10.1016/j.bneo.2025.100088

Published: 2025

Journal Articles

Uemura Y, Yamamoto M, Ishimura M, et al. JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study. Blood Neoplasia . 2025;2(1):100053.

Blood Neoplasia (2025) 2 (2): 100084.

https://doi.org/10.1016/j.bneo.2025.100084

Published: 2025

Journal Articles

Replication of a GWAS signal near HLA-DQA2 with AML using a disease-only cohort and external population-based controls

Rose Laflamme, Véronique Lisi, Josée Hébert, Guy Sauvageau, Sébastien Lemieux, Vincent-Philippe Lavallée, Guillaume Lettre

Blood Neoplasia 100118.

https://doi.org/10.1016/j.bneo.2025.100118

Published: 2025

Includes: Supplemental data

Journal Articles

PPARγ-induced Upregulation of Fatty Acid Metabolism Confers Resistance to Venetoclax and Decitabine Therapy in AML.

Kotoko Yamatani, Tatsuro Watanabe, Kaori Saito, Abdullah Khasawneh, Abhishek Maiti, Zhihong Zeng, Kala Hayes, Shinya Kimura, Courtney D. DiNardo, Xiaoping Su, Shuko Nojiri, Yasushi Okazaki, Michael Andreeff, Marina Konopleva, Yoko Tabe

Blood Neoplasia 100121.

https://doi.org/10.1016/j.bneo.2025.100121

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes and factors influencing survival in patients with diffuse large B cell lymphoma: a population-based analysis

Inna Y Gong, Michael Crump, Anca Prica, Andrew Calzavara, Ning Liu, Tiana Kordbacheh, Danielle Rodin, David Hodgson, Lee Mozessohn, Matthew Cheung, John Kuruvilla

Blood Neoplasia 100117.

https://doi.org/10.1016/j.bneo.2025.100117

Published: 2025

Includes: Supplemental data

Journal Articles

NAMPT haploinsufficiency is a collateral lethal therapeutic vulnerability in high-risk myeloid malignancies with TP53 inactivation

Madhavi D. Senagolage, Hunter Z. Blaylock, Saira Khan, Sarah J. Skuli, Martin P. Carroll, Megan E. McNerney

Blood Neoplasia 100119.

https://doi.org/10.1016/j.bneo.2025.100119

Published: 2025

Includes: Supplemental data

Journal Articles

An Antibody-Drug Conjugate Targeting VpreB1 for the Treatment of B-cell Acute Lymphoblastic Leukemia

Peter M. Gordon, Robin L. Williams, Jason Ostergaard, Keegan C. Lee, Hannah N. Bui, Joseph M. Muretta, Bridget S. Wilson, Thomas Beder, Claudia D. Baldus, Luke Lambert, Benjamin E. Deonovic, Timothy Singleton, Sarah K. Tasian, Stuart S. Winter

Blood Neoplasia 100120.

https://doi.org/10.1016/j.bneo.2025.100120

Published: 2025

Includes: Supplemental data

Journal Articles

Real world performance of the CALGB 10403 regimen in young adults in the United States

Brandon DaSilva, Alicia Darwin, Amy Zhang, Rutu D. Vyas, Kathryn Russell, Jason S. Gilbert, Virginia Tan, Susan Feldt, Hannah Johnston, Emily C Liang, Adam S. DuVall, Michaela Liedtke, Wendy Stock, Ryan D. Cassaday, Marc Schwartz, Jessica T. Leonard, Lori S. Muffly, Marlise R. Luskin

Blood Neoplasia 100111.

https://doi.org/10.1016/j.bneo.2025.100111

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis

TYK2 is essential for the therapeutic effect of IFN-α in Jak2 V617F-induced murine myeloproliferative neoplasms

Tumor-associated myeloid cells support murine T-ALL in the central nervous system via integrin signaling

Risk factors and clinical impact of cytomegalovirus DNAemia in patients with multiple myeloma treated with teclistamab

Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm

A Phase 1 Study of IO-202, an Anti-LILRB4 Antibody, in Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia

Correlates of Organ Damage in Advanced Systemic Mastocytosis Patients Enrolled in Clinical Trials of Avapritinib

Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: A Danish population-based study

Targeting scavenger receptor class B type 1 with a bioinspired ligand induces apoptosis or ferroptosis in AML

V-FAST: A phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML

Beat AML genetic risk stratification model in an older VEN/HMA-treated AML patient cohort

Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma.

Moura PL, Nannya Y, Aliouat A, et al. Competition of dual SF3B1 mt clones in MDS-RS is associated with distinct RNA mis-splicing in hematopoietic stem cells. Blood Neoplasia. 2024;1(2):100011.

Uemura Y, Yamamoto M, Ishimura M, et al. JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study. Blood Neoplasia . 2025;2(1):100053.

Replication of a GWAS signal near HLA-DQA2 with AML using a disease-only cohort and external population-based controls

PPARγ-induced Upregulation of Fatty Acid Metabolism Confers Resistance to Venetoclax and Decitabine Therapy in AML.

Outcomes and factors influencing survival in patients with diffuse large B cell lymphoma: a population-based analysis

NAMPT haploinsufficiency is a collateral lethal therapeutic vulnerability in high-risk myeloid malignancies with TP53 inactivation

An Antibody-Drug Conjugate Targeting VpreB1 for the Treatment of B-cell Acute Lymphoblastic Leukemia

Real world performance of the CALGB 10403 regimen in young adults in the United States

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only